Doctors Challenge BMA's Stance on Puberty Blocker Treatments
Around one thousand senior doctors have expressed disappointment with the British Medical Association's stance on gender services, particularly regarding puberty blockers. The doctors support the Cass Review, which recommended more comprehensive mental health support and found weak evidence for medical interventions. Meanwhile, NHS England and the government have halted routine puberty blocker prescriptions and are implementing new measures in response to the review.
About 1,000 senior doctors, including some former heads of Royal Colleges, have written to the British Medical Association (BMA) expressing 'extreme disappointment' over its stance on gender services.
The BMA, following a Council vote, opposes a ban on puberty blocker treatments and has called for a pause on reforms suggested by a recent review led by Dr. Hilary Cass.
Dr. Cass's review, commissioned by NHS England and published in April, found weak evidence supporting medical interventions for children and recommended a broader model including mental health support.
Shortly before the review, the Tavistock clinic offering gender services in England and Wales was closed.
NHS England ceased routine prescribing of puberty blockers and announced a government ban.
In August, NHS England responded to the Cass Review by planning eight new centres and a clinical trial on puberty blockers.
While health leaders broadly welcomed these measures, the BMA called for a pause and further review.
Organizers of the letter accuse the BMA of being 'opaque and secretive,' not reflecting its wider membership's views.
BMA Council Chairman Prof. Philip Banfield stated that the concerns raised would be considered but criticized the rapid and selective implementation of the Cass Review proposals.
The BMA, following a Council vote, opposes a ban on puberty blocker treatments and has called for a pause on reforms suggested by a recent review led by Dr. Hilary Cass.
Dr. Cass's review, commissioned by NHS England and published in April, found weak evidence supporting medical interventions for children and recommended a broader model including mental health support.
Shortly before the review, the Tavistock clinic offering gender services in England and Wales was closed.
NHS England ceased routine prescribing of puberty blockers and announced a government ban.
In August, NHS England responded to the Cass Review by planning eight new centres and a clinical trial on puberty blockers.
While health leaders broadly welcomed these measures, the BMA called for a pause and further review.
Organizers of the letter accuse the BMA of being 'opaque and secretive,' not reflecting its wider membership's views.
BMA Council Chairman Prof. Philip Banfield stated that the concerns raised would be considered but criticized the rapid and selective implementation of the Cass Review proposals.
